{"id":1541,"date":"2025-10-12T20:14:44","date_gmt":"2025-10-13T00:14:44","guid":{"rendered":"https:\/\/www.madischu.com\/?p=1541"},"modified":"2025-10-12T20:14:44","modified_gmt":"2025-10-13T00:14:44","slug":"promising-therapy-in-parkinsons-disease","status":"publish","type":"post","link":"https:\/\/www.life360coach.com\/index.php\/2025\/10\/12\/promising-therapy-in-parkinsons-disease\/","title":{"rendered":"Promising Therapy in Parkinson&#8217;s Disease"},"content":{"rendered":"<div>\n<div class=\"css-175oi2r r-1wbh5a2 r-11niif6 r-bnwqim r-13qz1uu\">\n<div class=\"css-175oi2r r-3pj75a\">\n<div class=\"css-146c3p1 r-bcqeeo r-1ttztb7 r-qvutc0 r-1qd0xha r-rjixqe r-16dba41 r-imh66m\" dir=\"ltr\">\n<div class=\"css-175oi2r\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1adg3ll r-1g7jtus r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1adg3ll r-1g7jtus r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, emerge as promising therapeutic agents in Parkinson&#8217;s disease (PD).<br \/>\nThey target the gut-brain axis, mitigating alpha-synuclein (\u03b1-syn) pathology, reducing neuroinflammation, and enhancing dopaminergic function.<br \/>\nPD patients exhibit gut dysbiosis with reduced SCFA-producing bacteria (e.g., <\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274 r-36ujnk\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Faecalibacterium prausnitzii<\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">, <\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274 r-36ujnk\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Roseburia<\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"> spp.) and lower fecal\/plasma SCFA levels, correlating with motor severity, progression, and non-motor symptoms like constipation and depression.<br \/>\nSCFAs counteract these via HDAC inhibition, GPCR activation (e.g., FFAR2\/3, GPR109A), and barrier restoration, with preclinical models showing neuroprotection and symptom alleviation.<br \/>\nRecent advances in 2024\u20132025, including prodrug conjugates and microbiome modulation, position SCFAs as adjuncts to levodopa, addressing dysbiosis-driven treatment resistance.<br \/>\n<\/span><\/span><\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-adyw6z r-135wba7 r-b88u0q\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><strong><br \/>\nKey Mechanisms<\/strong><br \/>\n<\/span><\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1adg3ll r-1x3r274 r-p1pxzi\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">SCFAs influence PD through interconnected pathways, primarily<span style=\"text-decoration: underline;\"> via microbial metabolite signaling<\/span>:<\/span><\/span><\/span><\/p>\n<ul dir=\"ltr\">\n<li><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><strong><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-b88u0q r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Epigenetic and Neuroprotective Effects<\/span><\/span><\/strong><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><strong>:<\/strong><br \/>\nButyrate inhibits HDACs, upregulating BDNF\/GDNF and promoting autophagy (e.g., via PGC-1\u03b1), which degrades \u03b1-syn aggregates and protects dopaminergic neurons in MPTP\/rotenone models.<br \/>\nPropionate activates FFAR3 to boost GLP-1 secretion, enhancing motor function and reducing neurodegeneration.<\/span><\/span><\/li>\n<li><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><strong><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-b88u0q r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Anti-Inflammatory and Immune Modulation<\/span><\/span><\/strong><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><strong>:<\/strong><br \/>\nSCFAs shift microglia from M1 (proinflammatory) to M2 phenotypes via GPR109A\/NF-\u03baB inhibition, suppressing cytokines (IL-6, TNF-\u03b1) and ROS\/RNS-induced oxidative stress.<br \/>\nThey promote Treg differentiation and curb gut-to-brain \u03b1-syn propagation by stabilizing intestinal barriers (upregulating ZO-1\/claudins).<\/span><\/span><\/li>\n<li><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><strong><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-b88u0q r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Gut Microbiome and Barrier Integrity<\/span><\/span><\/strong><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><strong>:<\/strong><br \/>\nSCFAs restore eubiosis, inhibit L-dopa-metabolizing bacteria (e.g., <\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274 r-36ujnk\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Enterococcus faecalis<\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">), and enhance vagal signaling for parasympathetic tone, alleviating constipation and systemic inflammation.<\/span><\/span><\/li>\n<li><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><strong><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-b88u0q r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">\u03b1-Synuclein Modulation<\/span><\/span><\/strong><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><strong>:<\/strong><br \/>\nButyrate reduces phosphorylated \u03b1-syn in the substantia nigra via C\/EBP\u03b2 suppression and autophagy, limiting transneuronal spread from ENS to the brain.<\/span><\/span><\/li>\n<\/ul>\n<p><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1adg3ll r-1g7jtus r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">These mechanisms are bidirectional:<br \/>\nPD dysbiosis depletes SCFAs, exacerbating pathology, while SCFA supplementation reverses deficits in germ-free\/transplant models.<br \/>\n<\/span><\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-adyw6z r-135wba7 r-b88u0q\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><strong>Evidence from Preclinical and Clinical Studies:<\/strong><br \/>\n<\/span><\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1adg3ll r-1g7jtus r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Recent studies highlight SCFAs&#8217; efficacy, with a shift toward targeted delivery and microbiome integration.<br \/>\nBelow is a summary of key 2024\u20132025 findings:<\/span><\/span><\/span><\/p>\n<div class=\"css-175oi2r r-xoduu5 r-1ifxtd0 r-lltvgl r-bnwqim r-13qz1uu\">\n<table>\n<tbody>\n<tr>\n<th>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Study Type\/Source<\/span><\/span><\/div>\n<\/th>\n<th>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Key Findings<\/span><\/span><\/div>\n<\/th>\n<th>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Model\/Population<\/span><\/span><\/div>\n<\/th>\n<th>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Outcomes\/Implications<\/span><\/span><\/div>\n<\/th>\n<\/tr>\n<tr>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-b88u0q r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Preclinical: Honokiol-SCFA Conjugates<\/span><\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"> (Scientific Reports, Jun 2025)<\/span><\/span><\/div>\n<\/td>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Ester prodrugs (e.g., HNK-BAc) hydrolyzed by gut esterases release HNK\/SCFAs, inhibiting <\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274 r-36ujnk\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">E. faecalis<\/span><\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"> growth (dose-dependent delay, MIC 180 \u00b5M for HNK-Ac) and L-dopa-to-dopamine conversion, preserving bioavailability. Induce membrane hyperpolarization and transient ATP modulation without cytotoxicity.<\/span><\/span><\/div>\n<\/td>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">In vitro (<\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274 r-36ujnk\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">E. faecalis<\/span><\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"> cultures); no in vivo yet<\/span><\/span><\/div>\n<\/td>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Enhances levodopa efficacy; synergistic neuroprotection via AMPK-Sirt3 (HNK) and HDAC inhibition (SCFAs). Proposes gut-targeted adjunct therapy; future MitoPark mouse trials needed.<\/span><\/span><\/div>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-b88u0q r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Review: SCFAs-PD Pathogenesis<\/span><\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"> (Front Neurol, 2024; updated insights 2025)<\/span><\/span><\/div>\n<\/td>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Reduced SCFAs correlate with \u03b1-syn aggregation, BBB leakage, and Th17\/Treg imbalance. Butyrate rescues TH expression\/dopamine in 6-OHDA\/MPTP models; propionate protects via FFAR3\/GLP-1. Dual effects: anti-inflammatory at low doses, potential exacerbation at high in sterile conditions.<\/span><\/span><\/div>\n<\/td>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">MPTP mice, rotenone Drosophila, germ-free models<\/span><\/span><\/div>\n<\/td>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Supports SCFA augmentation for early PD; links to non-motor symptoms (e.g., sleep via circadian entrainment).<\/span><\/span><\/div>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-b88u0q r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Mechanistic: \u03b1-Syn\/Neuroinflammation<\/span><\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"> (Redox Biol, 2024)<\/span><\/span><\/div>\n<\/td>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">SCFAs modulate \u03b1-syn-induced microglial ROS\/RNS and inflammation; lower SCFA levels in PD guts promote aggregation as early biomarker. Probiotics restore SCFAs, alleviating symptoms.<\/span><\/span><\/div>\n<\/td>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">PD patient microbiomes; in vitro microglia<\/span><\/span><\/div>\n<\/td>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Highlights gut-brain axis; probiotics as SCFA boosters for anti-aggregation therapy.<\/span><\/span><\/div>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-b88u0q r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Clinical Pilot: Tributyrin (SCFA Prodrug)<\/span><\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"> (NCT05446168, ongoing 2022\u20132025)<\/span><\/span><\/div>\n<\/td>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Open-label trial assesses oral tributyrin (SCFA precursor) for target engagement in PD, measuring plasma SCFAs, inflammation, and motor scores. Positive preclinical: restores microbiota balance.<\/span><\/span><\/div>\n<\/td>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">20 PD patients (Phase 1)<\/span><\/span><\/div>\n<\/td>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Aims to support larger SCFA supplementation studies; potential for symptom relief via gut modulation.<\/span><\/span><\/div>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-b88u0q r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Clinical Pilot: Prebiotic SR001<\/span><\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"> (NCT07127120, Aug 2025 initiation)<\/span><\/span><\/div>\n<\/td>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Single-arm trial of prebiotic targeting SCFA-producers (e.g., butyrate via fibers) to evaluate microbiome shifts, fecal SCFAs, and PD progression markers.<\/span><\/span><\/div>\n<\/td>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">30 early PD patients<\/span><\/span><\/div>\n<\/td>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Focuses on beneficial metabolites as fuel; early data may inform dietary interventions for dysbiosis.<\/span><\/span><\/div>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-b88u0q r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">FMT\/SCFA Regulation<\/span><\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"> (Front Microbiol, Jun 2025)<\/span><\/span><\/div>\n<\/td>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">FMT upregulates FFAR2\/3, elevating SCFAs and reducing neuroinflammation in PD models; correlates with motor improvements.<\/span><\/span><\/div>\n<\/td>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">\u03b1-Syn-overexpressing mice<\/span><\/span><\/div>\n<\/td>\n<td>\n<div class=\"css-175oi2r r-1adg3ll r-11f147o r-faml9v\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\">Validates microbiota transfer for SCFA restoration; therapeutic for prodromal PD.<\/span><\/span><\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-adyw6z r-135wba7 r-b88u0q\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><br \/>\n<strong>Therapeutic Applications<\/strong><br \/>\n<\/span><\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1adg3ll r-1g7jtus r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">SCFAs offer non-invasive, microbiome-centric strategies, often combined with standard care:<\/span><\/span><\/span><\/p>\n<ul dir=\"ltr\">\n<li><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><strong><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-b88u0q r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Direct\/Indirect Supplementation<\/span><\/span><\/strong><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><strong>:<\/strong><br \/>\n&#8211; Oral butyrate (500\u20132000 mg\/day) or prodrugs like tributyrin improve motor scores in models;<br \/>\n&#8211; Prebiotics (e.g., inulin, resistant starch) boost endogenous production by 20\u201350%, enhancing barriers and GLP-1.<\/span><\/span><\/li>\n<li><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><strong><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-b88u0q r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Probiotics\/Synbiotics<\/span><\/span><\/strong><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"><strong>:<\/strong> Strains like <\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274 r-36ujnk\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Bifidobacterium breve<\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"> or <\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274 r-36ujnk\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">L. rhamnosus<\/span><\/span><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\"> GG increase SCFAs, reducing \u03b1-syn and inflammation in MPTP mice; RCTs show 15\u201330% UPDRS improvements.<\/span><\/span><\/li>\n<li><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><strong><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-b88u0q r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Novel Conjugates<\/span><\/span><\/strong><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">: HNK-SCFA esters target dysbiosis and L-dopa resistance, with hydrophobicity aiding delivery; 2025 pilots explore oral dosing.<\/span><\/span><\/li>\n<li><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><strong><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-b88u0q r-1x3r274\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Dietary Interventions<\/span><\/span><\/strong><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">: High-fiber Mediterranean diets elevate SCFAs, correlating with slower PD progression (e.g., negative association with H&amp;Y scores).<\/span><\/span><\/li>\n<\/ul>\n<p><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1adg3ll r-1x3r274 r-p1pxzi\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3\"><span class=\"css-1jxf684 r-bcqeeo r-1ttztb7 r-qvutc0 r-poiln3 r-1x3r274\">Doses are well-tolerated (up to 4 g\/day butyrate), but variability arises from microbiome baseline.<br \/>\nChallenges include absorption (colonic targeting via enemas) and context-dependent effects (e.g., inflammation in low-diversity guts).<br \/>\nFuture trials (e.g., Phase II for conjugates) integrate multi-omics for personalization, potentially delaying progression by 20\u201340% via early gut intervention.<\/span><\/span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"css-175oi2r r-18u37iz r-1wtj0ep r-1s2bzr4 r-11niif6 r-1udh08x r-3o4zer r-bnwqim r-13qz1uu\">\n<div class=\"css-175oi2r r-1habvwh r-1h0z5md\">\n<div class=\"css-175oi2r r-1awozwy r-18u37iz r-1wtj0ep r-13qz1uu\">\n<div class=\"css-175oi2r r-1awozwy r-18u37iz\">\n<div class=\"css-175oi2r\">\n<div class=\"css-146c3p1 r-bcqeeo r-qvutc0 r-1qd0xha r-q4m81j r-a023e6 r-rjixqe r-b88u0q r-1awozwy r-6koalj r-18u37iz r-16y2uox r-1777fci\" dir=\"ltr\">Source: Grok X AI<\/div>\n<\/div>\n<div class=\"css-175oi2r\">\n<div class=\"css-146c3p1 r-bcqeeo r-qvutc0 r-1qd0xha r-q4m81j r-a023e6 r-rjixqe r-b88u0q r-1awozwy r-6koalj r-18u37iz r-16y2uox r-1777fci\" dir=\"ltr\">Read about <a href=\"https:\/\/www.life360coach.com\/gut-dysbiosis-in-parkinsons-disease\/\">Gut Dysbiosis in Parkinson&#8217;s Disease<\/a><\/div>\n<\/div>\n<div class=\"css-146c3p1 r-bcqeeo r-qvutc0 r-1qd0xha r-q4m81j r-a023e6 r-rjixqe r-b88u0q r-1awozwy r-6koalj r-18u37iz r-16y2uox r-1777fci\" dir=\"ltr\"><\/div>\n<div class=\"css-175oi2r r-18u37iz r-1jnkns4\">\n<div class=\"css-146c3p1 r-bcqeeo r-qvutc0 r-1qd0xha r-q4m81j r-a023e6 r-rjixqe r-b88u0q r-1awozwy r-6koalj r-18u37iz r-16y2uox r-1777fci\" dir=\"ltr\"><\/div>\n<div class=\"css-146c3p1 r-bcqeeo r-qvutc0 r-1qd0xha r-q4m81j r-a023e6 r-rjixqe r-b88u0q r-1awozwy r-6koalj r-18u37iz r-16y2uox r-1777fci\" dir=\"ltr\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"css-175oi2r r-6y1tle r-6koalj r-eqz5dr r-9aw3ui r-12kyg2d r-11niif6 r-u9wvl5 r-13qz1uu\">\n<div class=\"css-175oi2r r-u8s1d r-1krgy4v r-ocobd0\" data-testid=\"follow_ups_list\">\n<div class=\"css-175oi2r\" data-testid=\"placementTracking\">\n<div class=\"css-175oi2r r-109y4c4 r-11j9u27 r-92ng3h\"><\/div>\n<\/div>\n<\/div>\n<div class=\"css-175oi2r r-1awozwy r-k200y r-1g4g62n r-yn5ncy r-dzk0um r-1ec6tlx r-6y1tle r-6koalj r-18u37iz r-1cmwbt1 r-11f147o r-bnwqim r-8kqaxe\">\n<div class=\"css-146c3p1 r-dnmrzs r-1udh08x r-1udbk01 r-3s2u2q r-bcqeeo r-1ttztb7 r-qvutc0 r-1qd0xha r-a023e6 r-rjixqe r-16dba41 r-homxoj\" dir=\"ltr\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, emerge as promising therapeutic agents in Parkinson&#8217;s disease (PD). They target the gut-brain axis, mitigating alpha-synuclein (\u03b1-syn) pathology, reducing neuroinflammation, and enhancing dopaminergic function. PD patients exhibit gut dysbiosis with reduced SCFA-producing bacteria (e.g., Faecalibacterium prausnitzii, Roseburia spp.) and lower fecal\/plasma SCFA levels, correlating with motor [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18,40],"tags":[45,56,115],"class_list":["post-1541","post","type-post","status-publish","format-standard","hentry","category-diseases","category-gut-microbiome","tag-gut-microbiome","tag-parkinsons-disease","tag-short-chain-fatty-acids"],"_links":{"self":[{"href":"https:\/\/www.life360coach.com\/index.php\/wp-json\/wp\/v2\/posts\/1541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.life360coach.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.life360coach.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.life360coach.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.life360coach.com\/index.php\/wp-json\/wp\/v2\/comments?post=1541"}],"version-history":[{"count":0,"href":"https:\/\/www.life360coach.com\/index.php\/wp-json\/wp\/v2\/posts\/1541\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.life360coach.com\/index.php\/wp-json\/wp\/v2\/media?parent=1541"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.life360coach.com\/index.php\/wp-json\/wp\/v2\/categories?post=1541"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.life360coach.com\/index.php\/wp-json\/wp\/v2\/tags?post=1541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}